The biotechnology company BioVentures Institute in cooperation with the University of Gdansk have developed a globally unique molecular technology for the construction of recombinant vaccines and new generation biological drugs. This innovative technology is currently being used to develop the COVID-19 vaccine.
Innovative technology is based on the construction of artificial (i.e. non-existent in nature) proteins using vector-enzymatic, organized duplication encoding DNA segment epitopes.
The new biotechnology was created as a result of the implementation of a scientific project co-financed by the National Center for Research and Development as part of the Innovative Economy Operational Program. Both technology and research results have been patented.
